Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SF0003
- Development stage
- Preclinical
- Lead developer
- Sarfez Pharmaceuticals
- Modality
- Small Molecules
01
Overview
SF0003 is an investigational small molecule diuretic being developed by Sarfez Pharmaceuticals for the treatment of hypertension, heart failure with reduced ejection fraction (HFrEF), and chronic kidney disease (CKD). Currently in the IND-enabling phase of development, SF0003 is part of a specialized pipeline at Sarfez Pharmaceuticals focused on addressing unmet needs in cardiovascular and renal medicine, particularly regarding fluid management and blood pressure control. While the specific molecular target (such as NKCC2 or NCC) has not been publicly disclosed, the candidate is categorized as a diuretic therapy intended to manage fluid overload and improve outcomes in patients with heart and kidney failure.
Beyond the preview
Go deeper on SF0003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SF0003.